AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe

Zacks11-18

AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer. The EC has approved...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484578606?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/J5PJq8rtkuiBcDVdnbD5LA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227","is_english":true,"pubTime":"2024-11-18 23:17","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484578606","market":"us","top_or_hot":-1,"title":"AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe","media":"Zacks","content":"<div>\n<p>AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer.\nThe EC has approved...</p>\n\n<a href=\"https://finance.yahoo.com/news/abbvies-ovarian-cancer-drug-elahere-151700486.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-18 23:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/abbvies-ovarian-cancer-drug-elahere-151700486.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer.\nThe EC has approved...</p>\n\n<a href=\"https://finance.yahoo.com/news/abbvies-ovarian-cancer-drug-elahere-151700486.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B4R5TH58.HKD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/abbvies-ovarian-cancer-drug-elahere-151700486.html","article_id":"2484578606","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/J5PJq8rtkuiBcDVdnbD5LA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484578606","pubTimestamp":1731943020,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"AbbVie ABBV announced that the European Commission  has granted marketing authorization to Elahere  for treating platinum-resistant ovarian cancer.The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatments.Following the approval, Elahere became the first and only FRα-directed antibody drug conjugate  approved specifically for patients with FRα positive, platinum-resistant ovarian cancer in the European Union.Elahere was granted full approval by the FDA for a similar indication in March 2024. The drug was initially approved for this indication under the accelerated pathway in 2022.Shares of AbbVie have gained 6.5% so far this year compared with the industry’s rise of 3.4%.Some better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, ANI Pharmaceuticals, Inc. ANIP and","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","ADC":"艾格里房产","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","CHMP":"冠军工业","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4585":"ETF&股票定投概念","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","ABBV":"艾伯维公司","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4007":"制药","CSTL":"Castle Biosciences, Inc.","BK4196":"保健护理服务","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","SG9999015978.USD":"利安颠覆性创新基金A","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0861579265.USD":"联博低波幅策略股票基金A","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","BK4231":"零售房地产信托","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","IMCR":"Immunocore Holdings plc","BK4505":"高瓴资本持仓","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4581":"高盛持仓","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"艾伯维卵巢癌药物Elahere在欧洲获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"IMCR":1,"CSTL":1,"CHMP":1,"ABBV":1,"ANIP":1},"content_text":"AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer.\nThe EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatments.\nFollowing the approval, Elahere became the first and only FRα-directed antibody drug conjugate (ADC) approved specifically for patients with FRα positive, platinum-resistant ovarian cancer in the European Union.\nElahere was granted full approval by the FDA for a similar indication in March 2024. The drug was initially approved for this indication under the accelerated pathway in 2022.\nShares of AbbVie have gained 6.5% so far this year compared with the industry’s rise of 3.4%.\nImage Source: Zacks Investment Research\nEU Nod Based on ABBV's MIRASOL Study\nThe latest approval in Europe was based on data from the phase III MIRASOL study, which evaluated Elahere against the investigator's choice of single-agent chemotherapy in the given patient population.\nData from the study showed that treatment with Elahere reduced the risk of tumor progression or death by 35% compared with investigator's choice of chemotherapy — the primary endpoint of the MIRASOL study.\nAlso, treatment with Elahere improved overall survival — demonstrating a 33% reduction in the risk of death versus the investigator's choice of chemotherapy.\nThe approval in Europe was expected as in September the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had recommended approval for Elahere for the given indication.\nMore Updates on ABBV's Elahere\nA first-in-class ADC, Elahere, was added to AbbVie’s portfolio in February this year following the acquisition of ImmunoGen for $10.1 billion.\nADCs are next-generation treatments that target cancer cells by delivering highly potent cancer-killing agents through a targeted antibody.\nIn June, AbbVie reported positive results from the phase II PICCOLO study, which evaluated Elahere in heavily pre-treated patients with FRα-positive platinum-sensitive ovarian cancer. The study achieved its primary endpoint as patients treated with Elahere achieved an objective response rate of 51.9%.\nElahere generated sales worth $331 million during the first nine months of 2024. The drug is also being studied for earlier lines of therapy in ovarian cancer. Potential label expansion of the drug is likely to boost sales in future quarters.\nABBV's Zacks Rank & Key Picks\nAbbVie currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, ANI Pharmaceuticals, Inc. ANIP and Castle Biosciences, Inc. CSTL, each carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Immunocore’s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time. Year to date, shares of IMCR have declined 53.8%.\nIMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 25.57%.\nIn the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have moved up from $4.59 to $4.71. Earnings per share estimates for 2025 have improved from $4.82 to $5.65 during the same time. Year to date, shares of ANIP have increased 2.6%.\nANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.27%.\nIn the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time. Year to date, shares of CSTL have surged 30.2%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAbbVie Inc. (ABBV) : Free Stock Analysis Report\nANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nImmunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484578606"}